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Abstract
Background: Pulmonary hypertension (PH) is a known co-morbidity in West Highland white terriers (WHWTs)
affected with canine idiopathic pulmonary fibrosis (CIPF). The pulmonary vein-to-right pulmonary artery ratio (PV/
PA) has recently been described for the detection of pre-capillary PH in dogs. The objective of the present study
was to estimate the prevalence of PH at diagnostic, in WHWTs affected with CIPF, by using PV/PA, in comparison
with a group of healthy breed-matched controls (CTRLs). Additional study objective was to explore whether the
presence of PH at initial diagnosis of CIPF impacted survival time in dogs treated with sildenafil.
Results: Twenty-five client-owned WHWTs presented with CIPF and 19 CTRLs were included in the study. PV/PA in
either two-dimensional mode (2D) or time-motion mode or both were measured from cineloops in each dog.
Dogs were classified according to PV/PA value into non/mild PH (PV/PA measured in 2D ≥ 0.7) or moderate/severe
PH (PV/PA < 0.7). Survival data of WHWTs affected with CIPF were extracted from medical record to assess
association between presence of PH at diagnosis and outcome. 60 % overall prevalence for moderate/severe PH
was estimated in this cohort of WHWTs presented with CIPF vs. 5 % in CTRLS (P = 0.0002). The presence of
moderate/severe PH at initial presentation was not associated with survival.
Conclusions: Results of the present study confirm a high prevalence of PH at diagnosis in WHWTs affected with
CIPF and highlight the utility of PV/PA as a non-invasive surrogate for assessment of PH in this population.
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1. Background
Canine idiopathic pulmonary fibrosis (CIPF) is a pro-
gressive fibrotic lung disease mainly reported in aged
West Highland white terriers (WHWTs) [1, 2]. CIPF
shares clinical, imaging and histopathological findings
from both human idiopathic pulmonary fibrosis (IPF)
and other interstitial lung diseases displaying non-
specific interstitial pneumonia pattern [1–5]. In human
IPF, pulmonary hypertension (PH) occurs in up to 85 %
of patients, depending on disease severity, evaluation
method and diagnostic criteria employed [6, 7]. The
presence of PH in human IPF patient has been associ-
ated with poorer quality of life, reduced cardiopulmo-
nary function and shorter survival time [8–10].
Right heart catheterization is considered as the gold
standard method of diagnosing PH but is not routinely
performed in clinical situations due to the invasiveness of
the procedure. Doppler-echocardiography can be used to
non-invasively assess pulmonary arterial pressures (PAP)
in the presence of tricuspid or pulmonic regurgitation by
applying the simplified Bernoulli equation [11]. However,
in the absence of a tricuspid or pulmonic regurgitant jet,
or in situation of poor Doppler alignment, this measure-
ment may be not feasible or inaccurate [12, 13].
Among the other echocardiographic parameters currently
available to non-invasively assess the presence of pre-
capillary PH, the pulmonary vein-to-right pulmonary artery
ratio (PV/PA) has recently been demonstrated to be one of
the most accurate at predicting PAP estimated by peak tri-
cuspid regurgitation systolic pressure gradient (TRPG) [14].
Indeed, PV/PA has been demonstrated to provide a good
accuracy for the diagnosis of moderate to severe pre-
capillary PH (defined as TRPG> 50mmHg) using a cutoff
value of < 0.70 (sensitivity = 96%, specificity = 82%) [14].
To the author’s knowledge, there has been only one
study, published over a decade ago, reporting an esti-
mated prevalence for PH of more than 44 % in WHWTs
affected with CIPF [15]. There has been no report study-
ing the association between the presence of PH at diag-
nosis and survival in WHWTs affected with CIPF.
We hypothesized that PH occurs at a high prevalence
rate in WHWTs affected with CIPF at initial diagnosis
and has a negative impact on survival. The primary aim of
this study was to estimate the prevalence of PH at diagno-
sis, in a cohort of WHWTs affected with CIPF, compared
with a group of breed-matched healthy controls (CTRLs)
using PV/PA echocardiographic parameter [14]. As a sec-
ondary aim, we explored whether the presence of PH at
initial diagnosis of CIPF impacted survival time.
2. Results
Dogs
Detailed features of the study population are summa-
rized in Table 1. Forty-four WHWTs were included in
the study: 25 WHWTs affected with CIPF and 19
CTRLs.
WHWTs affected with CIPF were older than CTRLs,
but there was no significant difference in gender reparti-
tion nor body weight between groups (Table 1). Two
CIPF WHWTs had arrhythmia (one dog with sick sinus
syndrome and another with second degree atrioventricu-
lar block), while none of the other dogs had significant
rhythm abnormalities other than sinus arrhythmia.
Among the 25 WHWTs affected with CIPF included, 17
(68 %) of them had a history of both exercise intolerance
and cough, 5 (20 %) had exercise intolerance alone and 3
(12 %) dogs exhibited cough only. Crackles were noticed
on lung auscultation in all CIPF WHWTs, restrictive
dyspnea was present in 15 (60 %) dogs, 6 of them exhi-
biting additional cyanosis. At the time of initial echocar-
diography, treatments started by the referring
veterinarian included prednisolone in 9 dogs (0.1–
0.7 mg/kg q12-72 h PO), pimobendan in 3 dogs
(0.2 mg/kg q12h PO), theophylline in 3 dogs (5–11 mg/
kg q12h PO), furosemide in 2 dogs (2 mg/kg q12h PO),
benazepril in 2 dogs (0.5–0.7 mg/kg q 24 h PO), spir-
onolactone in 1 dog (4 mg/kg q24h PO), codeine in 1
dog (1 mg/kg q12h PO), sildenafil in 1 dog (0.6 mg/kg
q24h PO) and antibiotics in 4 dogs. Thoracic high-
resolution computed tomography (HRCT) was per-
formed in 22/25 (88 %) WHWTs affected with CIPF and
revealed extensive ground-glass opacity in all of them.
Other thoracic HRCT findings included a combination
of mosaic pattern, bronchial wall thickening, consolida-
tion, parenchymal and subpleural bands, nodules and
bronchiectasis. Thoracic X-rays images were available in
the remaining 3 WHWTs affected with CIPF and dis-
played a severe diffuse broncho-interstitial pattern con-
sistent with the CIPF diagnosis.
CTRLs WHWTs were clinically healthy and did not
have any signs or findings indicating pulmonary or car-
diovascular disease. None of them were receiving treat-
ments. Thoracic HRCT was performed in 15/19 (79 %)
CTRLs and did not reveal significant abnormalities, ex-
cept for localized ground-glass opacity in cranial lung
lobes in 1 of them which was attributed to mild degree
of lung atelectasis. Among the 4 CTRLs without HRCT,
one had a thoracic X-rays available without reported ab-
normalities. The echocardiographic images and the elec-
trocardiogram were unremarkable in all dogs.
Echocardiographic results
Echocardiographic data are presented in Table 2. Echo-
cardiographic images for PV/PA measurements were ob-
tained in both 2-dimensional mode (2D) and time-
motion mode (MM) in 23/25 (92 %) CIPF WHWTs and
all CTRLs. Two CIPF WHWTs had the PV/PA
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measured either in 2D or MM only (1 dog respectively),
due to respiratory related artifacts. Using the cut-off
value for PV/PA measured in 2D of < 0.7 corresponding
to a TRPG > 50mmHg [14], moderate to severe PH was
identified in 15/24 (63 %) WHWTs affected with CIPF
and in 1/19 (5 %) CTRLs (P = 0.0002). The one WHWT
affected with CIPF for which PV/PA (2D) was not mea-
sured had a PV/PA (MM) of 0.960 and a TRPG of
28.4mmHg, suggesting the absence of PH. Accordingly,
the overall prevalence for moderate to severe PH in
WHWTs affected with CIPF was estimated at 60 %. A
tricuspid valve regurgitant jet was present in 12/25
(48 %) WHWTs affected with CIPF and in 5/19 (26 %)
CTRLs (P = 0.14). TRPG measured in WHWTs affected
with CIPF was in favor of none, mild or moderate PH in
respectively 3, 6 and 3 CIPF WHWTs [16]. All WHWTs
affected with CIPF with a TRPG indicative of moderate
PH had a PV/PA measured in 2D < 0.7. TRPG measured
in CTRLs indicated none or mild PH in 4 and 1 dog re-
spectively; PV/PA measured in 2D was ≥ 0.7 in all of
these dogs. A pulmonary valve regurgitant jet was
present in 4/25 (16 %) CIPF WHWTs and 1/19 (5 %)
CTRLs (P = 0.25). Only one of the CIPF affected
WHWTs had a peak pulmonary regurgitation pressure
gradient (PRPG) above 20mmHg, suggestive of an in-
crease in mean PAP [16]. This dog had a PV/PA < 0.7.
Survival
A total of 18 out of 25 WHWTs affected with CIPF died
by the end of the study period, 4 dogs were still alive,
and 3 dogs were lost of follow-up. The cause of death
was CIPF-related in 17 dogs (94 %) with an overall me-
dian survival time of 557 days (40–1538 days). Lung tis-
sue samples were available in 11 of these dogs (61 %)
and allowed the histopathological confirmation of the
CIPF diagnosis. There was no statistical difference in
survival between WHWTs affected with CIPF having
moderate to severe PH (median survival time 689 days;
95 % confidence interval (CI) = 260–1118 days) and
WHWTs affected with CIPF having no or mild PH (me-
dian survival time 733 days; CI = 553–913 days) (P =
0.528, Fig. 1) at diagnosis. Univariate Cox-regression
analysis revealed no significant effect of PV/PA mea-
sured in both modes on survival (hazard ration of 5.98
(CI = 0.36–100.80) and P = 0.198 for PV/PA measured in
2D; hazard ration of 3.78 (CI = 0.18–81.00) and P = 0.385
for PV/PA measured in MM).
3. Discussion
Assessment of PH can be challenging in veterinary
medicine as Doppler estimation of PAP via measure-
ment of TRPG is not always feasible or accurate [13].
This is particularly true in WHWTs affected with CIPF
as they are frequently presented with laborious breathing
that can impair proper Doppler beam alignment. In this
study, we used the newly described PV/PA echocardio-
graphic parameter as a surrogate diagnostic tool for pre-
capillary PH [14]. We estimated a 60 % overall preva-
lence for moderate to severe PH in our cohort of 25
WHWTs affected with CIPF by using this parameter.
The presence of moderate to severe PH at initial presen-
tation in this group of dogs was not associated with a
shorter survival.
After publication of PV/PA reference intervals in
healthy dogs [17, 18] and of its use for prediction of con-
gestive heart failure in mitral valve disease [18], our team
recently described the use of PV/PA (measured in 2D)
to predict moderate to severe pre-capillary PH (TRPG >
50 mmHg) [14]. PVPA was proven to predict PH with a
good diagnostic accuracy (AUC 0.94) when compared
with other non-invasive echocardiographic parameters
Table 1 Characteristics of the study population
CIPF WHWTs (n = 25) Control WHWTs (n = 19) P-value
Sex, M/F 12/13 13/6 0.176
Age, years 10.6 +/- 2.5 8.5 +/- 2.8 0.009
Body weight, kg 9.6 (8.4–10.0) 9.0 (8.2–9.6) 0.255
CIPF, canine idiopathic pulmonary fibrosis; WHWTs, West Highland white terriers; M, male; F, female. Data are expressed as mean +/- standard deviation for
normally distributed data and as median and interquartile range for not normally distributed data
Table 2 Echocardiographic results
n CIPF WHWTs n Control WHWTs P-value
PV diam. (MM), mm 24 5.6 +/-1.6 19 7.6 +/- 1.6 < 0.001
PA diam. (MM), mm 24 9.0 +/- 0.8 19 7.5 +/- 0.8 < 0.001
PV/PA ratio (MM) 24 0.6 +/- 0.2 19 1.0 +/- 0.2 < 0.001
PV diam. (2D), mm 24 5.0 (3.9–5.6) 19 7.0 (6.1–7.3) < 0.001
PA diam. (2D), mm 24 8.5 (7.4–9.0) 19 7.0 (6.6–7.7) 0.001
PV/PA ratio (2D) 24 0.6 (0.5–0.7) 19 1.0 (0.9–1.0) < 0.001
TRPG, mmHg 12 41.2 +/- 16.2 5 26.2 +/- 15.4 0.100
PRPG, mmHg 4 14.0 +/- 10.2 1 4.8 +/- 0.0 0.477
CIPF, canine idiopathic pulmonary fibrosis; WHWT, West Highland whiter
terrier; PV, right pulmonary vein; MM, time-motion mode; PA, right pulmonary
artery; PV/PA, pulmonary vein to right pulmonary artery; 2D, 2-dimensional
mode; TRPG, peak tricuspid regurgitation systolic pressure gradient; PRPG,
peak pulmonary regurgitation diastolic pressure gradient. Data are expressed
as mean +/- standard deviation for normally distributed data and as median
and interquartile range for not normally distributed data
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of PH [14]. Applying the reported cut-off value of < 0.7 for
PV/PA measured in 2D [14], the overall prevalence for at
least moderate PH was estimated at 60 % in the presently
studied CIPF population. This finding is in agreement
with human IPF literature reporting a PH prevalence ran-
ging from 32 to 85 % according to studies [7]. This also
corroborated previously reported prevalence of > 44 % for
at least mild PH (according to TRPG value) in a cohort of
45 WHWTs affected with CIPF [15].
Using the same PV/PA cut-off value on a breed-
matched healthy CTRLs population, one out of the 19
included dogs (5 %) was classified as suffering from
moderate to severe PH. As this dog was clinically
healthy, this result most likely indicates a false-positive
and reflects the lack of specificity of the PV/PA param-
eter employed, previously reported at 82 % [14]. Another
healthy CTRL included in the present study was found
with a TRPG gradient indicative of mild PH. Although
Doppler measurement of TRPG generally tends to
underestimate PAP, overestimation is possible as dem-
onstrated by Soydan and associates (2015) [13]. Another
less likely explanation can be that these CTRLs dogs
were suffering, despite normal HRCT findings, from
subclinical early CIPF lesions at the time of echocardio-
graphic examination causing PH. Histopathological
examination of lung tissue and/or follow-up at regular
intervals would have been needed to answer this issue,
but was not performed.
A mean/median value of 1 for PV/PA measured in
both modes was found in healthy CTRLs included in this
study, as previously reported in healthy dogs from other
breeds [17, 18]. Significantly lower PV/PA values were ob-
served in WHWTs affected with CIPF compared with
CTRLs, attributed to both an increase in the right pul-
monary artery (PA) size and a decrease in the right pul-
monary vein (PV) size (Table 2). This finding corroborates
previously reported observations in other causes of pre-
capillary PH, notably angiostrongylosis and bronchomala-
cia [14]. Enlarged PA size was previously discussed as a
possible consequence of increased pulmonary vascular
bed resistance due to the underlying lung disease, while
decreased PV size was speculated to stem from reduction
of left ventricular preload secondary to increased PAP,
from decrease right ventricular function, from compres-
sion of the vein by the enlarged adjacent artery, or some
combination of these factors [14].
Surprisingly, the presence of moderate to severe PH at
initial echocardiographic examination was not associated
with a shorter survival in our CIPF cohort. This finding
contrasts with the human literature where IPF patients
having PH had a significantly increased 1-year mortality
rate in comparison with IPF patients without PH (28 %
vs. 5.5 %) [19]. Another study also reported a three-fold
increase in mortality in IPF patients with PH, especially
when systolic PAP exceeds 50mmHg at echocardiog-
raphy [20]. This finding in CIPF dogs also differs from a
recent canine study about PH secondary to respiratory
disease, mainly obstructive airway/lung disease (81 % of
included dogs), where dogs with an estimated PAP ≥
47mmHg had significantly shorter survival than those <
Fig. 1 Survival time in CIPF WHWTs with moderate to severe and none to mild PH. Kaplan-Meier curves to compare survival time in days from
canine idiopathic pulmonary fibrosis (CIPF) diagnosis (x-axis) between West Highland white terriers (WHWTs) affected with CIPF with moderate to
severe pulmonary hypertension (PH) (group 1) (pulmonary veinto-right pulmonary artery ratio (PV/PA) measured in two-dimensional mode (2D) <
0.7) and WHWTs affected with CIPF with none to mild PH (group 2) (PV/PA measured in 2D ≥ 0.7). CIPF-related mortality: moderate to severe PH
median survival, 698 days; none to mild PH median survival, 733 days. Log-rank P-value of 0.528
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47mmHg [21]. The most likely explanation for the lack
of association between survival and PH in our cohort of
WHWTs affected with CIPF is that all WHWTs affected
with CIPF suffering from PH at diagnosis were subse-
quently treated with sildenafil and then regularly
followed as part of the CIPF-project to adjust treatment
recommendations. Sildenafil treatment in pre-capillary
PH has been shown to lower PAP from baseline, im-
prove quality of life, and expand likelihood of survival in
dogs [21–23]. Accordingly, sildenafil administration in
our cohort of CIPF WHWTs affected with pre-capillary
PH could have contributed to improved survival and
prevented identification of an association between the
presence of PH at diagnosis and outcome. Another ex-
planation for the lack of association with survival is that
the natural course of CIPF has been shown to vary
greatly from one dog to another, with WHWTs present-
ing either a rapid or a slow disease progression [24].
Whether the different types of disease progression are
influenced by underlying comorbidities such as PH is
currently unknow. Lastly, CIPF in dogs is not exactly the
same disease as IPF in humans as tomographic and his-
topathologic findings in CIPF have been shown to cover
both IPF and non-specific interstitial pneumonia pattern
characteristics [1–5]. Accordingly, the association be-
tween PH and survival can be different in CIPF than in
human IPF or than in other canine respiratory
conditions.
The main limitation of the present study was that PAP
were not directly measured by right heart catheterization
to assess the exact prevalence of mild, moderate and se-
vere PH at CIPF diagnosis. This technique was not
chosen because it is invasive, has inherent risk of com-
plications and would have required heavy sedation or
general anesthesia. Instead, PV/PA was chosen over
TRPG to estimate the presence of PH, as TRPG was un-
measurable in a substantial number of dogs which would
have led to an underestimation of the prevalence of PH.
The second limitation of the present study was that a
small proportion of WHWTs affected with CIPF in-
cluded were receiving cardiac or vasoactive drug therap-
ies at the time of echocardiography which could have
interfered with PV/PA measurements (e.g. diuretics po-
tentially reducing the PV size vs. sildenafil or pimoben-
dan potentially reducing the PA size). Two CIPF
WHWTs also had arrhythmias at the time of echocar-
diographic examination which could have impacted ves-
sels size and PV/PA measure. The small population size
was a third limitation, however given the suspected low
prevalence of CIPF in the WHWT breed population, this
patient cohort can be considered as relevant. Three
CTRL WHWTs did not have any imaging performed to
confirm the absence of pulmonary lesions. Pulmonary fi-
brosis was unlikely in these dogs as they were not
displaying any clinical signs of cardiorespiratory disease.
Lastly, echocardiographic parameters were assessed at
diagnosis in all included dogs to estimate prevalence of
PH at study inclusion. A follow-up study to assess the
incidence of PH in WHWTs affected with CIPF over
disease progression would have been interesting, but was
not performed in the present study.
4. Conclusions
Results of the present study revealed an estimated over-
all prevalence of 60 % for moderate to severe PH at diag-
nosis of CIPF as defined by the PV/PA
echocardiographic parameter. This high prevalence rate
for PH at diagnosis should encourage practitioner to
perform echocardiography on a regular basis in
WHWTs presented with suspicion of CIPF. The pres-
ence of PH at diagnosis was not associated with survival
in WHWTs affected with CIPF. Further studies are
needed to determine the utility of PV/PA in the long-
term monitoring of WHWTs affected with CIPF for
assessing the incidence of PH development in the course
of the disease or assessing the effects of targeted therapy.
5. Methods
Dogs
In order to estimate the PH prevalence at diagnosis
using PV/PA, in WHWTs affected with CIPF compared
with a group of breed-matched healthy controls and ex-
plored whether the presence of PH at diagnosis of CIPF
impacted survival time, client-owned WHWTs pre-
sented with CIPF and CTRLs were enrolled at the Small
Animal Veterinary Clinic of the University of Liège
under the umbrella of the CIPF project1 between April
2012 and November 2018 with owner’s consent.
Dogs were retrospectively included in the present
study if PV/PA was recorded either on 2D or MM or
both during initial echocardiographic examination. Dogs
with a concomitant left- or right-sided cardiac disease
were excluded.
WHWTs affected with CIPF were diagnosed according
to a previously described approach [25]. CIPF diagnosis
was based on history, presence of crackles on lung aus-
cultation, and compatible thoracic imaging findings.
Diagnosis was further confirmed by lung histopathology
for dogs who died during the study period and for which
lung tissue was available. WHWTs affected with CIPF
were subdivided into two groups according to PV/PA
echocardiographic evidence of pre-capillary PH: non/
mild PH group (PV/PA measured in 2D ≥ 0.7) and mod-
erate/severe PH group (PV/PA measured in 2D < 0.7).
Breed-matched control dogs were recruited if healthy
with no previous history of cardiovascular or pulmonary
1See: http://www.canineidiopathicpulmonaryfibrosis.ulg.ac.be.
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disease and normal general and cardiopulmonary phys-
ical examination. All dogs recruited under the umbrella
of the CIPF project had an echocardiographic study per-
formed as part of their initial investigation.
Echocardiographic examination
Transthoracic 2D, MM and conventional Doppler-
echocardiography were performed by three trained ob-
servers including two board-certified veterinary cardiolo-
gists (KME and ACM) and one cardiology assistant
under the direct supervision of a board-certified veterin-
ary cardiologist, using an ultrasound unit (Vivid I, Gen-
eral Electric Medical System, Machelen, Belgium)
equipped with 2.2–3.5 and 5.5–7.5 MHz phased-array
transducers. Dogs were placed in right and left lateral re-
cumbency and a simultaneous one-lead electrocardio-
gram was recorded. Standard right parasternal (long and
short axis) and left apical parasternal views were used
for echocardiographic data acquisition.
Echocardiographic measurements were retrospectively
performed off-line by a single trained investigator
(KME). As previously described [14, 17, 18] and illus-
trated [14], a right parasternal long axis four-chamber
view was optimized to simultaneously record both PV
and PA vessels. Dimensions of both vessels were ob-
tained as previously described [14]. An average of at
least 3 representative measurements of PV and PA di-
ameters were taken in MM and 2D to calculate PV/PA
ratios [14, 18]. Peak systolic tricuspid regurgitant jet vel-
ocity, when present, was measured using continuous
wave Doppler from the view that allowed the best align-
ment to calculate TRPG. The highest value of tricuspid
regurgitant jet velocity was recorded. A similar tech-
nique was used to record pulmonary regurgitation, when
present, using continuous wave Doppler positioned cen-
trally in the flow stream between the opened pulmonic
valve leaflets and measure the PRPG.
Survival analysis
Outcome data were obtained from clinical records for
WHWTs affected with CIPF. Death was defined as
CIPF-related if dogs were euthanized or died due to clin-
ical signs of progressive respiratory failure (dyspnea,
cyanosis, severe cough, extreme fatigability, syncope,
etc.). The decision to euthanize was made by the owners
if dog’s quality of life could not be maintained. Euthan-
asia were performed in a standard manner using pre-
medication with butorphanol 0.3 mg/kg IV, anesthesia
induction with propofol 1 mg/kg IV and final lethal dose
of pentobarbital 200 mg/kg IV. Cardiopulmonary arrest
was confirmed by careful and prolonged cardiac
auscultation.
Statistical analysis
Statistical analyses were performed using XLstat (Addin-
soft SARL, Paris, France) and SPSS for Windows v25.0
(IBM Corp, Armonk, New York).
Continuous variables were reported as either mean +/-
standard deviation for normally distributed data or me-
dian and interquartile range for not normally distributed
data, and categorical data as proportions. The Shapiro-
Wilk test was applied to assess the normality of distribu-
tion of continuous variables. Differences in continuous
variables among CIPF and CTRLs WHWTs were deter-
mined using student’s t-test (for normally distributed
variables) or Mann-Whitney test (for variables that were
not normally distributed). Proportions were compared
between groups using the Chi-squared test. Survival
curves in days after CIPF diagnosis were drawn with the
Kaplan-Meier method. Dogs that were still alive on the
last date of follow-up or dead for another reason than
CIPF were censored. Dogs lost to follow-up were in-
cluded until the last day of known follow-up, at which
point they were censored. Univariate tests for compari-
son of groups of survival data were made with the log-
rank test and with a proportional hazard logistic regres-
sion model for continuous data. For all analyses, P-
value ≤ 0.05 was considered statistically significant.
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